Doug Daniels is the group leader for protein science and structural biology within the Broad Institute’s Therapeutics Projects Group (TPG). In this role, Daniels has overseen the establishment of a new protein science team with scientists dedicated to the design, expression, purification, and biophysical characterization of challenging therapeutic targets. He is also building a similar group that will enable the platform’s efforts in structural biology.
The TPG brings together experts from academia and industry to drive innovation in solving complex therapeutics challenges. The protein science and structural biology team supports all protein-related TPG projects, including PCSK9, which is targeting the traditionally “undruggable” PCSK9 pathway in an effort to develop therapeutics for coronary artery disease, and MCL1 and ERG, both of which are testing targets for cancer therapeutics.
Prior to joining the Broad Institute in 2012, Daniels led cross-functional discovery teams for biological therapeutics in the metabolic disease area at the Novartis Institutes for Biomedical Research. There, he contributed to the engineering and optimization of a protein therapeutic scheduled for clinical trials. His lab also supported the creation and biophysical characterization of proteins as both therapeutics and therapeutic targets.
Daniels holds a B.S. from the University of Michigan and completed his Ph.D. in molecular and structural biology at The Scripps Research Institute. He also completed a postdoctoral fellowship with Alanna Schepartz at Yale University.